You are here

  • Home
  • Archive
  • Volume 93, Issue 1
  • Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Article metrics

Article menu
Download PDFPDF
Multiple sclerosis
Original research
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

 

Online download statistics by month:

Online download statistics by month: August 2021 to September 2024

AbstractFullPdf
Aug 202120501969486
Sep 202144041297
Oct 2021429394109
Nov 202122318678
Dec 2021597582119
Jan 2022602577167
Feb 2022272263120
Mar 2022164152102
Apr 202218116547
May 202214313463
Jun 202211610534
Jul 202214513238
Aug 202212211128
Sep 202216914450
Oct 202214312767
Nov 2022906730
Dec 202211510436
Jan 20231059525
Feb 20231049823
Mar 20231317925
Apr 202312885
May 202319357
Jun 20237491
Jul 202311252
Aug 202311462
Sep 202313294
Oct 202313553
Nov 2023174123
Dec 2023219117
Jan 202410742
Feb 20249743
Mar 2024118176
Apr 2024171106
May 202413613
Jun 20249554
Jul 202414763
Aug 20247713
Sep 20248211
Total865260151809